sickle cell disease
Sickle Cell Drug Oxbryta Withdrawn From Market
Pfizer is voluntarily withdrawing its SCD medication Oxbryta from the market due to safety concerns.
SEPTEMBER 27, 2024
‘Low-Intensity’ Blood Stem Cell Transplants May Improve Lung Function in Sickle Cell
Low-intensity blood SCTs, which use milder conditioning agents than standard SCTs, may approve lung function in ...
SEPTEMBER 10, 2024
Who Will Pay for Sickle Cell Gene Therapy?
The December 2023 FDA approval of the first two gene therapies to treat sickle cell disease was a giant step ...
FEBRUARY 23, 2024
FDA Approves First Gene Therapies to Treat Patients With Sickle Cell Disease
The FDA approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients ...
DECEMBER 8, 2023
A Record Pace Seen for 2023 Specialty Approvals
The FDA appears to be making up for lost time after the COVID-19 pandemic. The agency is on schedule to approve 51 ...
DECEMBER 4, 2023
Options Growing for Managing Sickle Cell Disease
Sickle cell disease causes significant pain and other complications among approximately 100,000 U.S. residents and ...
OCTOBER 13, 2023
New Therapies and Better Access Urgently Needed For Sickle Cell Patients
Americans with SCD have been largely neglected, experts say, particularly once they reach adulthood.
NOVEMBER 21, 2022
For Sickle Cell Patients, The Struggle Continues
Kevin Wake understands all too well the disparities in healthcare that prevail in the United States, especially for ...
AUGUST 12, 2022
High-Risk Sickle Cell Disease Patients: Get Vaccinated
New research finds that certain factors, such as a history of severe pain episodes and coexisting organ conditions, ...
SEPTEMBER 22, 2021
Gene Therapy May Someday Treat Sickle Cell Disease
Researchers are converting a pathogenic hemoglobin gene to a benign variant that enables healthy blood cell ...
JUNE 18, 2021
‘An Exciting Time’ to Manage Sickle Cell Disease
Sickle cell disease (SCD) affects approximately 100,000 people living in the United States—double the number ...
MAY 26, 2020
FDA Approves Novel Treatment for Abnormality in Sickle Cell Disease
Oxbryta inhibits deoxygenated sickle hemoglobin polymerization, which is the central abnormality in sickle cell ...
NOVEMBER 26, 2019
